COMPARISON OF FASTING BLOOD GLUCOSE AND C-REACTIVE PROTEIN LEVELS BETWEEN FIRST DEGREE RELATIVES OF TYPE 2 DIABETIC PATIENTS WITH IHD AND WITHOUT IHD- CRP AS AN INDEPENDENT MARKER FOR IHD

##plugins.themes.academic_pro.article.sidebar##

Published Sep 20, 2022
Download
PDF
Statistic

Downloads

Download data is not yet available.
Vol. 5 No. 05 (2022): International Journal of Medical Science in Clinical Research and Review

##plugins.themes.academic_pro.article.main##

Jaswant Kaur
assistant professor

Abstract

Background:-CRP is an important inflammatory marker in the pathogenesis of metabolic disorders. One of the major complications in diabetes mellitus patients is cardiovascular disease. CRP may help to predict among Pre-diabetic patients are at higher risk for Ischemic heart disease (IHD). Several cumulative studies indicate that CRP levels are altered in individuals with a family history of diabetes. The aim of this study was to explore the comparison and association of CRP levels between the first degree relatives of type-2 diabetes with IHD and without IHD patients.


Material and method: - The present study access fasting Blood glucose levels and inflammatory marker CRP in two groups. Group A comprised 50 first degree relatives of type 2 diabetes with IHD and Group B consist of 50 first degree relatives of type 2 diabetes without IHD.


Result: -The mean of CRP and Fasting Blood Sugar were significantly (p<0.05) higher in 1st degree relative to type 2 diabetic patients with IHD.  It also seems to be slightly elevated levels of CRP in 1st degree relatives of type 2 diabetics without IHD.


Conculsion: - The study has shown that CRP is an independent marker in early diagnosis of IHD in 1st degree relatives of type 2 diabetics. It has also been seen that strong family history of type 2 diabetic patients who are in Pre-diabetic stage has shown slightly increased level of CRP and patients have fasting sugar level is within the normal range when we compare the two parameters FBS and CRP in pre-diabetics patients. So, we can use CRP as an important diagnostic tool for the prevention of IHD in those patients who have a family history of diabetes.


 

##plugins.themes.academic_pro.article.details##

How to Cite
Kaur, J. (2022). COMPARISON OF FASTING BLOOD GLUCOSE AND C-REACTIVE PROTEIN LEVELS BETWEEN FIRST DEGREE RELATIVES OF TYPE 2 DIABETIC PATIENTS WITH IHD AND WITHOUT IHD- CRP AS AN INDEPENDENT MARKER FOR IHD. International Journal of Medical Science in Clinical Research and Review, 5(05), Page: 593–598. Retrieved from http://ijmscrr.in/index.php/ijmscrr/article/view/285

References

    1. National Diabetes Data Group (1979). Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28, 1039-1057
    2.King H, Aubert RE, Herman WH .Global burden of diabetes,1995-2025:Prevalence ,numerical estimates and projections, Diabetes Care.1998;21:1414-1431.
    3. Wild S, Roglic G , Green A, Sicree R, King H. Global prevalence of diabetes , Estimation for the year 2000 and projections for 2030.Diabetes Care ,2004; 27:1047-1053.
    4.Bertuzzi M, Negri E, Tavani A, La Vecchia C. family history of ischemic heart disease and risk of acute myocardial infarction. Prev Med 2003; 37:183-187.
    5.Expert panel on blood rheology , guidelines on selection of laboratory tests for monitoring the acute phase response.jclinpathol. 1988;41:1203-1212.

    6. Abbas Dehgan, Isabella Carddys, MoniekPM,et al. :Genetic variations, C-reactive protein and risk of type 2 diabetes. Diabetes,2005; 70:126-31.

    7.Freeman, D. J. et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the west of scotland coronary prevention study. Diabetes. 51, 1596–1600 (2002).

    8.W Koenig, C-reactive Protein: Risk Assessment in the Primary Prevention of Atherosclerotic Disease. Has the Time Come for Including It in the Risk Profile?Ital Heart j 2001 Mar;2(3):157-63.
    9. Devaraj S, Xu DY, jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells implications the metabolic syndrome and atherothrombosis .circulation 2003;107 :398-404
    10.Kowalska I, Prokop J, Bachorzewska-Gajewska H et al. Disturbances of glucose metabolism in men referred for coronary arteriography. Postloadglycemia as predictor for coronary atherosclerosis. Diabetes Care 2001;24:897-901.
    11.HayansiH,Longrippo GA,H. CRP latex test for qualitative and quantitative estimation of C-Reactive Protein in human serum sample. Ford Hosp.Med.1950;8:445.
    12. Mehta SR, Kashyap AS, Das S. Diabetes Mellitus in India: The Modern Scourge. MJAFI; 65(1):50-54.
    13. Pickup JC.Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes . Diabetes Care 2004;27:813-823.
    14.Abdelmouttaleb I, Danchin N, Ilardo C, Aimone-Gastin I, Angioi M, Lozniewski A, Loubinoux J, Le Faou A, Gueant JL: C-reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J 137:346–351, 1999

    15.Ridker PM, Rifai N, Lowenthal SP: Rapid reduction of C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103:1191–1193, 2001
    16.Ridker PM, Glynn RJ, Hennekens CH: C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97:2007–2011, 1998
    17.M. B. Pepys and G. M. Hirschfield, “C-reactive protein: a critical update,” The Journal of Clinical Investigation, vol. 111, no. 12, pp. 1805–1812, 2003.
    18.T.W.du Clos, “Pentraxins: structure, function, and role in inflammation,” ISRN Inflammation, vol. 2013, Article ID 379040, 22 pages, 2013.
    19. Libby P. Mechanisms of acute coronary syndromes and their 11. Implications for therapy . N Engl J Med.2013;368:2004-13.
    20. Pfutzner A, Forst T. High sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. DiabTechnolTher 2006;8(1):28-36.
    21. American Diabetes association . Consensus statement:role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes .Diab care,1993;16:72-8.
    22. Rivellese AA, Riccardi G, Vaccaro O. cardiovascular risk in women with diabetes .NutritMetabolCardiovasc Dis.2010;20(6):474-80.
    23. Duncan B, Schmidt M, Pankow J, Ballantyne C. Atherosclerosis risk in communities study. Low- grade systemic inflammation and the development of type 2 diabetes : the atherosclerosis risk in communities study . Diab.2003;52:1799-05.
    24.Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (July 2001). "C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus". JAMA. 286 (3):327-34.

    25.Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands EJ, Bootsma AH, et al. (March 2007). "Genetic variation, C-reactive
    26. Ridker PM, Buring JE, Cook NR. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy Am women. Circulation. 2003;107:391-7.
    27. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003;107:398-404.
    28. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-8.
    29. King DE, Mainous AG, Buchanan TA, Pearson WS.C-reactive protein and glycemic control in adults with diabetes. Diabe Care. 2003;26(5):1535-9
    30. Gohel MG, Chacko AN. Serum GGT activity and hs-CRP level in patients with type 2 diabete mellitus with good and poor glycemic control: An evidence linking oxidative stress, inflammation and glycemic control. J Diabe Metabolic Dis.2013;12:56.
    31. Kashinakunti SV, Rangappa M, Kallaganada GS. International J Biochem Res Rev. 2016;11(4): 1-8
    32. Wierusz- Wysocka B, Wysocki H, et al. Metabolic control quality and free radical in diabetic patients. Diabetes Res ClinPract 1995;25:193-197.
    33. Bell DS: Inflammation, insulin resistance, diabetes, and atherosclerosis. Endocr Pract.2000,6:272-276.